Kamada Company Profile (NASDAQ:KMDA)

About Kamada

Kamada logoKamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KMDA
  • CUSIP:
Key Metrics:
  • Previous Close: $5.24
  • 50 Day Moving Average: $4.55
  • 200 Day Moving Average: $4.03
  • 52-Week Range: $3.24 - $5.34
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 87.33
  • P/E Growth: -4.34
  • Market Cap: $190.83M
  • Outstanding Shares: 36,418,000
  • Beta: 1.16
Profitability:
  • Net Margins: -9.92%
  • Return on Equity: -10.59%
  • Return on Assets: -7.24%
Debt:
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 3.55%
  • Quick Ratio: 2.24%
Additional Links:
Companies Related to Kamada:

Analyst Ratings

Consensus Ratings for Kamada (NASDAQ:KMDA) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.50 (62.21% upside)

Analysts' Ratings History for Kamada (NASDAQ:KMDA)
Show:
DateFirmActionRatingPrice TargetDetails
9/3/2016HC WainwrightReiterated RatingBuy$10.00View Rating Details
8/31/2016Jefferies GroupReiterated RatingBuy$7.00View Rating Details
1/7/2015Royal Bank Of CanadaSet Price TargetBuy$8.00View Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for Kamada (NASDAQ:KMDA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2016Q216($0.04)($0.04)$18.50 million$19.10 millionViewN/AView Earnings Details
2/2/2016Q415($0.09)$0.03$27.10 million$25.90 millionViewN/AView Earnings Details
11/10/2015Q315($0.04)($0.13)$18.67 million$16.10 millionViewListenView Earnings Details
7/30/2015Q215($0.03)($0.06)$21.82 million$19.20 millionViewListenView Earnings Details
5/12/2015Q115($0.05)($0.15)$16.12 million$9.00 millionViewListenView Earnings Details
2/11/2015Q4$0.01$0.05ViewN/AView Earnings Details
11/13/2014Q314($0.04)($0.09)$19.00 million$17.20 millionViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.23)$17.17 million$15.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.03)($0.09)$15.97 million$13.20 millionViewN/AView Earnings Details
2/5/2014Q413$0.05$0.04$25.22 million$24.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kamada (NASDAQ:KMDA)
Current Year EPS Consensus Estimate: $-0.19 EPS
Next Year EPS Consensus Estimate: $0.06 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.11)($0.11)($0.11)
Q2 20161($0.04)($0.04)($0.04)
Q3 20161($0.01)($0.01)($0.01)
Q4 20161$0.00$0.00$0.00
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Kamada (NASDAQ:KMDA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kamada (NASDAQ:KMDA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Kamada (NASDAQ:KMDA)
DateHeadline
finance.yahoo.com logoLifeSci Capital Initiates Coverage of Kamada (NASDAQ:KMDA)
finance.yahoo.com - September 12 at 5:38 PM
finance.yahoo.com logoKamada to Present a Corporate Overview at the Rodman & Renshaw 18th Annual Investment Conference (NASDAQ:KMDA)
finance.yahoo.com - September 9 at 10:35 AM
thestreet.com logo4 Biotechs Set to Provide a Shot in the Arm (NASDAQ:KMDA)
realmoney.thestreet.com - September 9 at 10:35 AM
benzinga.com logoH.C. Wainwright Talks Kamada's Recent Phase 2 Results (NASDAQ:KMDA)
www.benzinga.com - September 1 at 5:42 PM
seekingalpha.com logoMarketing application filed in U.S. for Kamada's post-exposure rabies therapy; launch planned in 2017 (NASDAQ:KMDA)
seekingalpha.com - September 1 at 8:54 AM
publicnow.com logoKamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment (NASDAQ:KMDA)
www.publicnow.com - September 1 at 8:54 AM
News IconKamada succeeds in phase 2 inhaled drug trial (NASDAQ:KMDA)
www.globes.co.il - August 31 at 10:40 AM
streetinsider.com logoKamada (KMDA): Phase II Trial Adds Support For Inhaled AAT Therapy - Jefferies (NASDAQ:KMDA)
www.streetinsider.com - August 31 at 10:40 AM
nasdaq.com logoKamada's Phase 2 Trial Of Alpha-1 Antitrypsin Therapy Meets Primary Endpoint (NASDAQ:KMDA)
www.nasdaq.com - August 30 at 9:06 AM
seekingalpha.com logoMid-stage study of Kamada's inhaled AAT therapy in AATD successful; shares up 7% premarket (NASDAQ:KMDA)
seekingalpha.com - August 30 at 9:06 AM
streetinsider.com logoKamada's (KMDA) Inhaled Alpha-1 Antitrypsin Phase 2 Met Primary Endpoint (NASDAQ:KMDA)
www.streetinsider.com - August 30 at 9:06 AM
publicnow.com logoKamada Meets Primary Endpoint of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of Alpha-1 Antitrypsin Deficiency (NASDAQ:KMDA)
www.publicnow.com - August 30 at 9:06 AM
feeds.benzinga.com logoKamada's Phase 2 Trial On Inhaled Alpha-1 Antitrypsin Meets Primary Endpoint (NASDAQ:KMDA)
feeds.benzinga.com - August 30 at 8:38 AM
4-traders.com logoBiotest : Kamada recalls imported drug (NASDAQ:KMDA)
www.4-traders.com - August 17 at 6:02 PM
News IconKamada recalls imported drug (NASDAQ:KMDA)
www.globes.co.il - August 16 at 9:06 AM
News IconOur Take On Kamada Ltd (KMDA)’s Upcoming Catalysts (NASDAQ:KMDA)
feedproxy.google.com - August 9 at 1:02 PM
capitalcube.com logoKamada Ltd. :KMDA-IL: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 (NASDAQ:KMDA)
www.capitalcube.com - August 9 at 8:53 AM
capitalcube.com logoKamada Ltd. :KMDA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:KMDA)
www.capitalcube.com - August 5 at 6:00 PM
publicnow.com logoKamada Reports Financial Results for the Second Quarter and First Six Months of 2016 (NASDAQ:KMDA)
www.publicnow.com - August 3 at 9:04 AM
sg.finance.yahoo.com logoKamada reports 2Q loss (NASDAQ:KMDA)
sg.finance.yahoo.com - August 2 at 10:42 AM
capitalcube.com logoETF’s with exposure to Kamada Ltd. : July 26, 2016 (NASDAQ:KMDA)
www.capitalcube.com - July 26 at 12:50 PM
finance.yahoo.com logoKamada to Host Second Quarter Financial Results Conference Call on August 2, 2016 at 8:30 am Eastern Time (NASDAQ:KMDA)
finance.yahoo.com - July 26 at 12:19 PM
finance.yahoo.com logoKamada Announces Appointment of Naveh Tov, M.D., Ph.D., to Vice President, Clinical Development and Medical Director for Pulmonary Diseases (NASDAQ:KMDA)
finance.yahoo.com - June 23 at 7:00 AM
seekingalpha.com logoFDA approves self-infusion of Glassia (NASDAQ:KMDA)
seekingalpha.com - June 15 at 5:52 PM
capitalcube.com logoKamada Ltd. :KMDA-US: Earnings Analysis: Q1, 2016 By the Numbers (NASDAQ:KMDA)
www.capitalcube.com - May 12 at 12:49 PM
publicnow.com logoKamada Reports 2016 First Quarter Financial Results (NASDAQ:KMDA)
www.publicnow.com - May 9 at 6:56 AM
sg.finance.yahoo.com logoKamada reports 1Q loss (NASDAQ:KMDA)
sg.finance.yahoo.com - May 9 at 6:34 AM
News IconNew Kamada CEO optimistic despite European setback (NASDAQ:KMDA)
www.globes.co.il - May 5 at 9:09 AM
finance.yahoo.com logoKamada to Host First Quarter Financial Results Conference Call on May 9, 2016 at 8:30 am Eastern Time (NASDAQ:KMDA)
finance.yahoo.com - May 4 at 8:30 AM
finance.yahoo.com logoKamada Receives Two Milestone Payments under Strategic Agreements with Chiesi Farmaceutici and Baxalta (NASDAQ:KMDA)
finance.yahoo.com - May 2 at 7:00 AM
streetinsider.com logoKamada (KMDA) Commences AAT Phase 2 for Lung Transplant Rejection Prevention (NASDAQ:KMDA)
www.streetinsider.com - April 7 at 1:40 PM
publicnow.com logoKamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection (NASDAQ:KMDA)
www.publicnow.com - April 7 at 7:02 AM
tmcnet.com logoKamada Submits Marketing Authorization Application with the European … (NASDAQ:KMDA)
www.tmcnet.com - March 30 at 2:32 PM
finance.yahoo.com logo6:30 am Kamada submits a Marketing Authorization Application with the EMA for its inhaled alpha-1 antitrypsin therapy as a treatment for AAT deficiency (NASDAQ:KMDA)
finance.yahoo.com - March 28 at 6:30 AM
finance.yahoo.com logoKamada Submits Marketing Authorization Application with the European Medicines Agency for its Proprietary Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency (NASDAQ:KMDA)
finance.yahoo.com - March 28 at 6:30 AM
capitalcube.com logoKamada Ltd. Earnings Analysis: 2015 By the Numbers (NASDAQ:KMDA)
www.capitalcube.com - February 5 at 12:35 PM
finance.yahoo.com logoKamada to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference (NASDAQ:KMDA)
finance.yahoo.com - February 5 at 8:56 AM
finance.yahoo.com logoNew Strong Buy Stocks for February 4th (NASDAQ:KMDA)
finance.yahoo.com - February 4 at 9:30 AM
sg.finance.yahoo.com logoKamada posts 4Q profit (NASDAQ:KMDA)
sg.finance.yahoo.com - February 2 at 7:37 AM
finance.yahoo.com logoKamada Reports 2015 Fourth Quarter and Full Year Financial Results (NASDAQ:KMDA)
finance.yahoo.com - February 2 at 7:17 AM
News Icon30 am Eastern time (NASDAQ:KMDA)
www.wallstreet-online.de - January 27 at 10:54 AM
finance.yahoo.com logoKamada to Host Fourth Quarter and Year End 2015 Financial Results Conference Call on February 2, 2016 at 8:30 am Eastern time (NASDAQ:KMDA)
finance.yahoo.com - January 27 at 10:41 AM
finance.yahoo.com logoKamada (KMDA) Reports Encouraging Data on Rabies Drug (NASDAQ:KMDA)
finance.yahoo.com - December 29 at 4:40 PM
capitalcube.com logoKamada Ltd. Earnings Analysis: Q3, 2015 By the Numbers (NASDAQ:KMDA)
www.capitalcube.com - December 23 at 1:12 PM
finance.yahoo.com logoNew Strong Sell Stocks for December 23rd (NASDAQ:KMDA)
finance.yahoo.com - December 23 at 9:30 AM
noodls.com logoKamada’s Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment (NASDAQ:KMDA)
www.noodls.com - December 23 at 8:17 AM
finance.yahoo.com logoKamada's rabies drug succeeds in trial (NASDAQ:KMDA)
finance.yahoo.com - December 23 at 6:17 AM
noodls.com logoKamada Completes Enrollment of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of AAT Deficiency (NASDAQ:KMDA)
www.noodls.com - December 9 at 6:17 AM
noodls.com logoKamada Provides Update on Alpha-1 Antitrypsin Development in Newly Diagnosed Type 1 Diabetes (NASDAQ:KMDA)
www.noodls.com - December 9 at 6:17 AM
finance.yahoo.com logoKAMADA LTD Financials (NASDAQ:KMDA)
finance.yahoo.com - December 8 at 1:09 PM

Social

Kamada (NASDAQ:KMDA) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff